March 2026 Quarterly Update and Appendix 4C
Filed with ASX · · 8 pages · English
Summary by 6ix AI
The company also reported net operating cash outflows for the quarter and provided insights into its ongoing research and development efforts. Overall, the filing serves to inform investors about the company's progress and financial status during the reporting period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Prescient Therapeutics
- Appendix 4D and Half Year Financial Report
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- September Quarterly Updated and Appendix 4C
Later from Prescient Therapeutics
- June 2026 Quarterly Update and Appendix 4C
- Appendix 4E and 2026 Annual Report
- Prescient Therapeutics Opens SPP to Raise $7m Today
- PTX-100 CTCL Phase 2a study reaches review milestone
- PTX Successfully Completes $6m Raise Via SPP and Placement
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics